Categories: Wire Stories

ShouTi Appoints Ding Ding, Ph.D., as Chief Financial Officer

SAN FRANCISCO & SHANGHAI–(BUSINESS WIRE)–ShouTi Inc., a clinical-stage biopharmaceutical company creating world-class small molecule medicines using advanced computational and structure-based technology, today announced the appointment of Ding Ding, Ph.D., as Chief Financial Officer (CFO). Dr. Ding will oversee the company�s investor relations and global financing activities. She joins ShouTi from Credit Suisse, where she served as the head of APAC Healthcare Investment Banking and Capital Markets.

“Dr. Ding is an accomplished financial executive with an exceptional track record in the global healthcare investment banking industry,” said Dr. Raymond Stevens, Ph.D., Chief Executive Officer. “Dr. Ding’s deep financial acumen and expertise both in the United States and in Asia will serve ShouTi well as we advance our pipeline of small molecule medicines for chronic diseases within the metabolic, cardiovascular and pulmonary therapeutic areas. We are thrilled to welcome her to our team, where her contributions will help position ShouTi for significant growth in the years ahead.”

Dr. Ding brings 20 years of experience in healthcare investment banking and equity research in New York, Hong Kong and Shanghai. She began her career in 2001 at UBS Warburg in US healthcare investment banking, and then as a research analyst covering US large cap pharma at Lehman Brothers. In 2010, Dr. Ding rejoined UBS as the head of China healthcare equity research, and then acted as the head of China healthcare investment banking for Barclays before joining Credit Suisse. Dr. Ding received her B.S. from Huazhong University of Science and Technology, MBA in finance from The Wharton School at the University of Pennsylvania, and Ph.D. in pharmacology and neuroscience from the State University of New York.

About ShouTi

ShouTi develops life-changing medicines for patients using advanced computational and structure-based technology. The company’s platform combines the latest advancements in computational chemistry, visualization of molecular interactions, and data integration to design orally available, superior medicines that overcome current limitations of biologic and peptide drugs. ShouTi is advancing its clinical-stage pipeline of differentiated treatments focused on chronic diseases with high unmet need, including cardiovascular, metabolic and pulmonary conditions. The ShouTi team’s deep experience with complex biological targets and mechanisms, structure-based drug design, and global drug discovery and development enables the company’s vision: to design and develop world-class medicines with high patient impact and broad commercial opportunity. For more information, visit www.shoutipharma.com and follow the company on Twitter @ShouTiPharma and LinkedIn.

Contacts

Media:
Ian Stone

Canale Communications

media@shoutipharma.com

Other inquiries:
Melita Sun Jung

Chief Business Officer

info@shoutipharma.com

Alex

Recent Posts

Mead Johnson Nutrition Hong Kong Reinforces Sustainability Commitment with Formula Cans Recycling Program

Reducing waste by collaborating with the World Green Organisation and a local farm to upcycle…

44 minutes ago

Trend Micro Safeguarding Cloud Data of Healthcare AI Innovation Leader

Offering security solutions protecting all cloud platforms: AWS, Azure, and Google Cloud HONG KONG SAR…

2 hours ago

68 per cent of Gen Zs not confident about maintaining good physical health in old age; least confident generation

Almost 1 in 2 Gen Zs are worried about mental health while 41 per cent…

2 hours ago

Social Enterprise Summit 2024 Collaborate and Innovate to Respond to Complex Social Issues and Shaping Hong Kong’s Social Entrepreneurship Ecosystem

“Connecting Global Experience, Strengthening Local Partnerships” HONG KONG SAR - Media OutReach Newswire - 25…

4 hours ago

Forvis Mazars celebrates new network formation in APAC, announces strong growth in Singapore

Global leaders converge in Singapore to mark new era of growth and collaboration SINGAPORE -…

6 hours ago

Dr. Nalinee Paiboon of Giffarine Receives Outstanding Leader Recognition at ACES Awards 2024

BANGKOK, THAILAND - Media OutReach Newswire - 25 November 2024 - Dr. Nalinee Paiboon, President…

8 hours ago